We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
-4.05%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$91.4M
AUM Growth
+$35.6M
(+64%)
Cap. Flow
+$43.1M
Cap. Flow
% of AUM
47.16%
Top 10 Holdings %
Top 10 Hldgs %
62.05%
Holding
42
New
9
Increased
17
Reduced
3
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$9.5M |
| 2 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$6.48M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$5.8M |
| 4 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$3.18M |
| 5 |
Guardant Health
GH
|
+$3.16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$2.72M |
| 2 |
Viatris
VTRS
|
+$2.67M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$1.72M |
| 4 |
Centene
CNC
|
+$1.71M |
| 5 |
AbbVie
ABBV
|
+$1.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.87% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
| $1.13M | 1.23% |
+762,219
| New | +$1.28M |
|
|
NCNA
27
NuCana
NCNA
$5.99M
| $1.08M | 1.19% |
37
+5
| +16% | +$138K |
|
|
28
Centene
CNC
$32.9B
| $969K | 1.06% |
16,318
-28,108
| -63% | -$1.71M |
|
29
Exicure
XCUR
$8.73M
| $157K | 0.17% |
707
-2,626
| -79% | -$831K |
|
|
30
AbbVie
ABBV
$438B
| – | – |
-18,921
| Closed | -$1.68M |
|
|
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-21,380
| Closed | -$655K |
|
32
eHealth
EHTH
$40.4M
| – | – |
-15,004
| Closed | -$1.23M |
|
|
ESPR
33
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-22,872
| Closed | -$1.36M |
|
34
Gilead Sciences
GILD
$165B
| – | – |
-20,791
| Closed | -$1.35M |
|
|
35
Insmed
INSM
$29.4B
| – | – |
-113,875
| Closed | -$2.72M |
|
|
36
Regeneron Pharmaceuticals
REGN
$83.2B
| – | – |
-4,584
| Closed | -$1.72M |
|
|
37
Viatris
VTRS
$18.7B
| – | – |
-132,855
| Closed | -$2.67M |
|
|
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-6,950
| Closed | -$896K |
|
|
VRAY
39
DELISTED
ViewRay, Inc.
VRAY
| – | – |
-256,205
| Closed | -$1.08M |
|
|
AERI
40
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-62,507
| Closed | -$1.51M |
|
|
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-49,431
| Closed | -$1.18M |
|
|
DERM
42
DELISTED
Dermira, Inc.
DERM
| – | – |
-81,127
| Closed | -$1.44M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Asymmetry Capital Management held 42 positions worth $91.4M, up 64% from $55.8M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Asymmetry Capital Management deployed $43.1M of net new capital in Q1 2020, opening 9 new positions and adding to 17 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 86,577 shares worth $4.42M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Centene, an estimated $1.71M trimmed.
- Asymmetry Capital Management's largest Q1 2020 buy was Global Blood Therapeutics, Inc.: 86,577 shares worth $4.42M.
- Asymmetry Capital Management added most to Arena Pharmaceuticals Inc in Q1 2020, an estimated $9.5M increase.
- Asymmetry Capital Management's biggest Q1 2020 reduction was Centene, cutting an estimated $1.71M.
- Asymmetry Capital Management fully exited Insmed in Q1 2020, selling an estimated $2.72M.
- Asymmetry Capital Management's ten largest holdings make up 62% of its $91.4M portfolio in Q1 2020.
- Asymmetry Capital Management opened 9 new positions and closed 13 in Q1 2020.
- Asymmetry Capital Management's portfolio value rose 64% quarter-over-quarter to $91.4M.
Based on Asymmetry Capital Management's 13F filing for Q1 2020, filed 13 May 2020.